Dr. Soliman Abdul Kader Fakeeh Hospital (4017) Fundamentals 2026 — P/E 30.7x, Revenue Analysis | SniperIQ
Dr. Soliman Abdul Kader Fakeeh Hospital (4017) is a SA-listed Healthcare company in Medical - Care Facilities with a market capitalization of SAR 7.9B, trading at SAR 34.40 on the SAU. This SniperIQ fundamentals page covers Dr. Soliman Abdul Kader Fakeeh Hospital's valuation (P/E 30.7x, P/B 2.5x), profitability (net margin 8.2%), revenue (SAR 3.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dr. Soliman Abdul Kader Fakeeh Hospital's market cap?
Dr. Soliman Abdul Kader Fakeeh Hospital (4017) has a market capitalization of approximately SAR 7.9B, trading at SAR 34.40 on the SAU. Market cap moves with the live share price.
What is Dr. Soliman Abdul Kader Fakeeh Hospital's P/E ratio?
Dr. Soliman Abdul Kader Fakeeh Hospital's trailing twelve-month P/E ratio is 30.7x, with a price-to-book (P/B) of 2.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Dr. Soliman Abdul Kader Fakeeh Hospital?
Dr. Soliman Abdul Kader Fakeeh Hospital runs a net profit margin of 8.2%, a gross margin of 21.4%, and an operating margin of 8.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dr. Soliman Abdul Kader Fakeeh Hospital generate?
Dr. Soliman Abdul Kader Fakeeh Hospital reported revenue of SAR 3.1B for fiscal year 2025, with net income of SAR 290M and earnings per share (EPS) of 1.26. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Dr. Soliman Abdul Kader Fakeeh Hospital pay a dividend?
Dr. Soliman Abdul Kader Fakeeh Hospital offers a trailing dividend yield of about 1.0%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Dr. Soliman Abdul Kader Fakeeh Hospital financially healthy?
Dr. Soliman Abdul Kader Fakeeh Hospital carries a debt-to-equity ratio of 0.40x and a current ratio of 1.65x, with a market beta of -0.17. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dr. Soliman Abdul Kader Fakeeh Hospital a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dr. Soliman Abdul Kader Fakeeh Hospital (4017) the key facts are: market cap SAR 7.9B, P/E 30.7x, revenue SAR 3.1B, 52-week range 27.2-42.84. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Dr. Soliman Abdul Kader Fakeeh Hospital's full fundamentals live
Get Dr. Soliman Abdul Kader Fakeeh Hospital's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.